Based on these findings, it is plausible that the ALT ≥ 25 IU/L group in our study included individuals with hepatic steatosis, inflammation, or fibrosis, in whom imeglimin exerted beneficial effects. The gene discussed is GPT; the disease is Hepatic steatosis.